Osimertinib plus chemotherapy improves PFS in advanced EGFR+ NSCLC
The combination of osimertinib (Tagrisso) and platinum-based chemotherapy led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with osimertinib alone in patients with locally advanced …
Osimertinib plus chemotherapy improves PFS in advanced EGFR+ NSCLC Read More